Non-CME Ancillary Events
ASRA Pain Medicine has provided space for these non-CME ancillary events. The programs were independently produced, not subject to review by ASRA Pain Medicine, and are not part of the scientific/educational program offered by ASRA Pain Medicine.
Thursday, 12:15-1:00 pm
Lunch Included, Encanto
Dual-NMR Agonists to Overcome the Current Shortfalls in the Management of Severe Acute Pain: BREAKING THE MOLD in Pain Biology
/tris-pharma-logo-2025.png?sfvrsn=15f6f03b_1 "tris pharma logo 2025"){kind=logo}
Moderate-to-severe acute pain is difficult to manage, with opioids often the only effective option despite their serious risks. Dual-NMR agonists, targeting both NOP and MOP receptors, are an emerging class of drugs that may deliver powerful pain relief with fewer side effects. Join us as we explore the latest clinical evidence and consider how this novel approach could transform the future of pain management.
Friday, 12:15-1:00 pm
Lunch Included, Phoenix DE
One Push for 48 Hours of PONV Prevention
Faculty: Omeed Khodaparast, MD, Anesthesiologist, Baylor Scott and White Medical Center – Uptown
Despite guideline-based prophylaxis, 20%-30% of patients still experience PONV, leading to extended PACU stays, clinical complications, unplanned admissions, and reduced patient satisfaction. At this symposium, you will learn about a proven, long-lasting, safe antiemetic, ideally suited to use as the foundation of a multimodal approach for patients at medium-to-high risk of developing PONV, with a 48-hour duration of action.
Friday, 12:15-1:00 pm
Lunch Included, Encanto
Exploring Sodium Channel Inhibition for the Management of Acute Pain
Faculty: Tricia Puppe, PhD, Senior Director Medical Affairs, Pain, Vertex Pharmaceuticals Incorporated, Boston, MA; Ian C. Weber, MD, Orthopedic Surgeon, The Joint Replacement Center at St. Anthony North Hospital, Westminster, CO; Karina Gritsenko, MD, Anesthesiologist and Professor of Anesthesiology, Montefiore Multidisciplinary Pain Program, Bronx, NY 
Please join us in this session to learn more about the role of suzetrigine, a nonopioid pain signal inhibitor, in the management of moderate-to-severe acute pain. We will explore the role of NaV1.8 in pain signaling, suzetrigine’s mechanism of action, and findings from our clinical studies evaluating suzetrigine. We will then gain clinical insights on the incorporation of its use in practice through discussions on real-world experience with suzetrigine.